APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rare Disease Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Rare Disease Therapeutic Market Analysis and Forecast 2026-2032

2 May 2026233 pages

Choose your research edition.

Industry ResearchRare Disease Therapeutic Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Rare Disease Therapeutic Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Rare Disease Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rare Disease Therapeutic Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Rare Disease Therapeutic Market Analysis and Forecast 2026-2032233 pages · $4,950 USD

Market perspective

The global Rare Disease Therapeutic market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Rare Disease Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Rare Disease Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Rare Disease Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Rare Disease Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Rare Disease Therapeutic include Bristol-Myers Squibb, Bayer, AstraZeneca, Pfizer, Novo Nordisk A/S, Sanofi SA, AbbVie, F Hoffmann-La Roche and Amgen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Rare Disease Therapeutic, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Rare Disease Therapeutic, also provides the revenue of main regions and countries. Of the upcoming market potential for Rare Disease Therapeutic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rare Disease Therapeutic revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rare Disease Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Rare Disease Therapeutic revenue, projected growth trends, production technology, application and end-user industry.

Rare Disease Therapeutic Segment by Company

Bristol-Myers Squibb

Bayer

AstraZeneca

Pfizer

Novo Nordisk A/S

Sanofi SA

AbbVie

F Hoffmann-La Roche

Amgen

Eisai

Novartis AG

Rare Disease Therapeutic Segment by Type

Biologics

Biosimilar

Small Molecules

Rare Disease Therapeutic Segment by Application

Hematologic Disease

Cancer

Infectious Disease

Cardiovascular Disease

Metabolic Disease

Endocrine Disease

Musculoskeletal Disease

Others

Rare Disease Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Rare Disease Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Rare Disease Therapeutic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rare Disease Therapeutic revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Rare Disease Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Biologics Major Player Table 3. Biosimilar Major Player Table 4. Small Molecules Major Player Table 5. Global Rare Disease Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hematologic Disease Major Player Table 7. Cancer Major Player Table 8. Infectious Disease Major Player Table 9. Cardiovascular Disease Major Player Table 10. Metabolic Disease Major Player Table 11. Endocrine Disease Major Player Table 12. Musculoskeletal Disease Major Player Table 13. Others Major Player Table 14. Rare Disease Therapeutic Industry Trends Table 15. Rare Disease Therapeutic Industry Drivers Table 16. Rare Disease Therapeutic Industry Opportunities and Challenges Table 17. Rare Disease Therapeutic Industry Restraints Table 18. Global Rare Disease Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Rare Disease Therapeutic Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Rare Disease Therapeutic Market Share by Region (2021-2026) Table 21. Global Rare Disease Therapeutic Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Rare Disease Therapeutic Market Share by Region (2027-2032) Table 23. Global Rare Disease Therapeutic Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Rare Disease Therapeutic Revenue Market Share by Players (2021-2026) Table 25. Global Rare Disease Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Rare Disease Therapeutic Key Players Headquarters & Area Served Table 27. Global Rare Disease Therapeutic Players, Product Type & Application Table 28. Global Rare Disease Therapeutic Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Rare Disease Therapeutic by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Rare Disease Therapeutic Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Rare Disease Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Rare Disease Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Rare Disease Therapeutic Revenue Market Share by Type (2021-2026) Table 35. Global Rare Disease Therapeutic Revenue Market Share by Type (2027-2032) Table 36. Global Rare Disease Therapeutic Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Rare Disease Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Rare Disease Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Rare Disease Therapeutic Revenue Market Share by Application (2021-2026) Table 40. Global Rare Disease Therapeutic Revenue Market Share by Application (2027-2032) Table 41. Bristol-Myers Squibb Company Information Table 42. Bristol-Myers Squibb Business Overview Table 43. Bristol-Myers Squibb Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Bristol-Myers Squibb Rare Disease Therapeutic Product Portfolio Table 45. Bristol-Myers Squibb Recent Development Table 46. Bayer Company Information Table 47. Bayer Business Overview Table 48. Bayer Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Bayer Rare Disease Therapeutic Product Portfolio Table 50. Bayer Recent Development Table 51. AstraZeneca Company Information Table 52. AstraZeneca Business Overview Table 53. AstraZeneca Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. AstraZeneca Rare Disease Therapeutic Product Portfolio Table 55. AstraZeneca Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Rare Disease Therapeutic Product Portfolio Table 60. Pfizer Recent Development Table 61. Novo Nordisk A/S Company Information Table 62. Novo Nordisk A/S Business Overview Table 63. Novo Nordisk A/S Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Novo Nordisk A/S Rare Disease Therapeutic Product Portfolio Table 65. Novo Nordisk A/S Recent Development Table 66. Sanofi SA Company Information Table 67. Sanofi SA Business Overview Table 68. Sanofi SA Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Sanofi SA Rare Disease Therapeutic Product Portfolio Table 70. Sanofi SA Recent Development Table 71. AbbVie Company Information Table 72. AbbVie Business Overview Table 73. AbbVie Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. AbbVie Rare Disease Therapeutic Product Portfolio Table 75. AbbVie Recent Development Table 76. F Hoffmann-La Roche Company Information Table 77. F Hoffmann-La Roche Business Overview Table 78. F Hoffmann-La Roche Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. F Hoffmann-La Roche Rare Disease Therapeutic Product Portfolio Table 80. F Hoffmann-La Roche Recent Development Table 81. Amgen Company Information Table 82. Amgen Business Overview Table 83. Amgen Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Amgen Rare Disease Therapeutic Product Portfolio Table 85. Amgen Recent Development Table 86. Eisai Company Information Table 87. Eisai Business Overview Table 88. Eisai Rare Disease Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Eisai Rare Disease Therapeutic Product Portfolio Table 90. Eisai Recent Development Table 91. Novartis AG Company Information Table 92. Novartis AG Business Overview Table 93. Novartis AG Rare Disease Therapeutic Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Novartis AG Rare Disease Therapeutic Product Portfolio Table 95. Novartis AG Recent Development Table 96. North America Rare Disease Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Rare Disease Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Rare Disease Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Rare Disease Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Rare Disease Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Rare Disease Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Rare Disease Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Rare Disease Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Rare Disease Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Rare Disease Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Rare Disease Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Rare Disease Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Rare Disease Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Rare Disease Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 110. China Rare Disease Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 111. China Rare Disease Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 112. China Rare Disease Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 113. China Rare Disease Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Rare Disease Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Rare Disease Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Rare Disease Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Rare Disease Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Rare Disease Therapeutic Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Rare Disease Therapeutic Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Rare Disease Therapeutic Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Rare Disease Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Rare Disease Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Rare Disease Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Rare Disease Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Rare Disease Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Rare Disease Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Rare Disease Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Rare Disease Therapeutic Image Figure 2. Global Rare Disease Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rare Disease Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 4. Biologics Image Figure 5. Biosimilar Image Figure 6. Small Molecules Image Figure 7. Global Rare Disease Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Rare Disease Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hematologic Disease Image Figure 10. Cancer Image Figure 11. Infectious Disease Image Figure 12. Cardiovascular Disease Image Figure 13. Metabolic Disease Image Figure 14. Endocrine Disease Image Figure 15. Musculoskeletal Disease Image Figure 16. Others Image Figure 17. Global Rare Disease Therapeutic Market Size (US$ Million) & (2021-2032) Figure 18. Global Rare Disease Therapeutic Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Rare Disease Therapeutic Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Rare Disease Therapeutic Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Rare Disease Therapeutic Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Rare Disease Therapeutic Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Rare Disease Therapeutic Revenue Market Share by Type (2021-2032) Figure 25. Global Rare Disease Therapeutic Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Rare Disease Therapeutic Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Rare Disease Therapeutic Revenue Market Share by Application (2021-2032) Figure 28. North America Rare Disease Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Rare Disease Therapeutic Revenue Share by Type (2021-2032) Figure 30. North America Rare Disease Therapeutic Revenue Share by Application (2021-2032) Figure 31. North America Rare Disease Therapeutic Revenue Share by Country (2021-2032) Figure 32. United States Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Rare Disease Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Rare Disease Therapeutic Revenue Share by Type (2021-2032) Figure 37. Europe Rare Disease Therapeutic Revenue Share by Application (2021-2032) Figure 38. Europe Rare Disease Therapeutic Revenue Share by Country (2021-2032) Figure 39. Germany Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Rare Disease Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Rare Disease Therapeutic Revenue Share by Type (2021-2032) Figure 49. China Rare Disease Therapeutic Revenue Share by Application (2021-2032) Figure 50. Asia Rare Disease Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Rare Disease Therapeutic Revenue Share by Type (2021-2032) Figure 52. Asia Rare Disease Therapeutic Revenue Share by Application (2021-2032) Figure 53. Asia Rare Disease Therapeutic Revenue Share by Region (2021-2032) Figure 54. Japan Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Rare Disease Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Rare Disease Therapeutic Revenue Share by Type (2021-2032) Figure 62. SAMEA Rare Disease Therapeutic Revenue Share by Application (2021-2032) Figure 63. SAMEA Rare Disease Therapeutic Revenue Share by Country (2021-2032) Figure 64. Brazil Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Rare Disease Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilar
  • Small Molecules
Applications
  • Hematologic Disease
  • Cancer
  • Infectious Disease
  • Cardiovascular Disease
  • Metabolic Disease
  • Endocrine Disease
  • Musculoskeletal Disease
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Bayer
  • AstraZeneca
  • Pfizer
  • Novo Nordisk A/S
  • Sanofi SA
  • AbbVie
  • F Hoffmann-La Roche
  • Amgen
  • Eisai
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Rare Disease Therapeutic Market by Type
  3. 1.2.1 Global Rare Disease Therapeutic Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Biologics
  5. 1.2.3 Biosimilar
  6. 1.2.4 Small Molecules
  7. 1.3 Rare Disease Therapeutic Market by Application
  8. 1.3.1 Global Rare Disease Therapeutic Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hematologic Disease
  10. 1.3.3 Cancer
  11. 1.3.4 Infectious Disease
  12. 1.3.5 Cardiovascular Disease
  13. 1.3.6 Metabolic Disease
  14. 1.3.7 Endocrine Disease
  15. 1.3.8 Musculoskeletal Disease
  16. 1.3.9 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Rare Disease Therapeutic Market Dynamics
  1. 2.1 Rare Disease Therapeutic Industry Trends
  2. 2.2 Rare Disease Therapeutic Industry Drivers
  3. 2.3 Rare Disease Therapeutic Industry Opportunities and Challenges
  4. 2.4 Rare Disease Therapeutic Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Rare Disease Therapeutic Market Perspective (2021-2032)
  2. 3.2 Global Rare Disease Therapeutic Growth Trends by Region
  3. 3.2.1 Global Rare Disease Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Rare Disease Therapeutic Market Size by Region (2021-2026)
  5. 3.2.3 Global Rare Disease Therapeutic Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Rare Disease Therapeutic Revenue by Players
  2. 4.1.1 Global Rare Disease Therapeutic Revenue by Players (2021-2026)
  3. 4.1.2 Global Rare Disease Therapeutic Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Rare Disease Therapeutic Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Rare Disease Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Rare Disease Therapeutic Key Players Headquarters & Area Served
  7. 4.4 Global Rare Disease Therapeutic Players, Product Type & Application
  8. 4.5 Global Rare Disease Therapeutic Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Rare Disease Therapeutic Market CR5 and HHI
  11. 4.6.3 2025 Rare Disease Therapeutic Tier 1, Tier 2, and Tier 3
5 Rare Disease Therapeutic Market Size by Type
  1. 5.1 Global Rare Disease Therapeutic Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Rare Disease Therapeutic Revenue by Type (2021-2032)
  3. 5.3 Global Rare Disease Therapeutic Revenue Market Share by Type (2021-2032)
6 Rare Disease Therapeutic Market Size by Application
  1. 6.1 Global Rare Disease Therapeutic Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Rare Disease Therapeutic Revenue by Application (2021-2032)
  3. 6.3 Global Rare Disease Therapeutic Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Rare Disease Therapeutic Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Rare Disease Therapeutic Product Portfolio
  12. 7.2.5 Bayer Recent Developments
  13. 7.3 AstraZeneca
  14. 7.3.1 AstraZeneca Company Information
  15. 7.3.2 AstraZeneca Business Overview
  16. 7.3.3 AstraZeneca Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Rare Disease Therapeutic Product Portfolio
  18. 7.3.5 AstraZeneca Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Rare Disease Therapeutic Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 Novo Nordisk A/S
  26. 7.5.1 Novo Nordisk A/S Company Information
  27. 7.5.2 Novo Nordisk A/S Business Overview
  28. 7.5.3 Novo Nordisk A/S Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novo Nordisk A/S Rare Disease Therapeutic Product Portfolio
  30. 7.5.5 Novo Nordisk A/S Recent Developments
  31. 7.6 Sanofi SA
  32. 7.6.1 Sanofi SA Company Information
  33. 7.6.2 Sanofi SA Business Overview
  34. 7.6.3 Sanofi SA Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sanofi SA Rare Disease Therapeutic Product Portfolio
  36. 7.6.5 Sanofi SA Recent Developments
  37. 7.7 AbbVie
  38. 7.7.1 AbbVie Company Information
  39. 7.7.2 AbbVie Business Overview
  40. 7.7.3 AbbVie Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AbbVie Rare Disease Therapeutic Product Portfolio
  42. 7.7.5 AbbVie Recent Developments
  43. 7.8 F Hoffmann-La Roche
  44. 7.8.1 F Hoffmann-La Roche Company Information
  45. 7.8.2 F Hoffmann-La Roche Business Overview
  46. 7.8.3 F Hoffmann-La Roche Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  47. 7.8.4 F Hoffmann-La Roche Rare Disease Therapeutic Product Portfolio
  48. 7.8.5 F Hoffmann-La Roche Recent Developments
  49. 7.9 Amgen
  50. 7.9.1 Amgen Company Information
  51. 7.9.2 Amgen Business Overview
  52. 7.9.3 Amgen Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Amgen Rare Disease Therapeutic Product Portfolio
  54. 7.9.5 Amgen Recent Developments
  55. 7.10 Eisai
  56. 7.10.1 Eisai Company Information
  57. 7.10.2 Eisai Business Overview
  58. 7.10.3 Eisai Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eisai Rare Disease Therapeutic Product Portfolio
  60. 7.10.5 Eisai Recent Developments
  61. 7.11 Novartis AG
  62. 7.11.1 Novartis AG Company Information
  63. 7.11.2 Novartis AG Business Overview
  64. 7.11.3 Novartis AG Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Novartis AG Rare Disease Therapeutic Product Portfolio
  66. 7.11.5 Novartis AG Recent Developments
8 North America
  1. 8.1 North America Rare Disease Therapeutic Revenue (2021-2032)
  2. 8.2 North America Rare Disease Therapeutic Revenue by Type (2021-2032)
  3. 8.2.1 North America Rare Disease Therapeutic Revenue by Type (2021-2026)
  4. 8.2.2 North America Rare Disease Therapeutic Revenue by Type (2027-2032)
  5. 8.3 North America Rare Disease Therapeutic Revenue Share by Type (2021-2032)
  6. 8.4 North America Rare Disease Therapeutic Revenue by Application (2021-2032)
  7. 8.4.1 North America Rare Disease Therapeutic Revenue by Application (2021-2026)
  8. 8.4.2 North America Rare Disease Therapeutic Revenue by Application (2027-2032)
  9. 8.5 North America Rare Disease Therapeutic Revenue Share by Application (2021-2032)
  10. 8.6 North America Rare Disease Therapeutic Revenue by Country
  11. 8.6.1 North America Rare Disease Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Rare Disease Therapeutic Revenue by Country (2021-2026)
  13. 8.6.3 North America Rare Disease Therapeutic Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Rare Disease Therapeutic Revenue (2021-2032)
  2. 9.2 Europe Rare Disease Therapeutic Revenue by Type (2021-2032)
  3. 9.2.1 Europe Rare Disease Therapeutic Revenue by Type (2021-2026)
  4. 9.2.2 Europe Rare Disease Therapeutic Revenue by Type (2027-2032)
  5. 9.3 Europe Rare Disease Therapeutic Revenue Share by Type (2021-2032)
  6. 9.4 Europe Rare Disease Therapeutic Revenue by Application (2021-2032)
  7. 9.4.1 Europe Rare Disease Therapeutic Revenue by Application (2021-2026)
  8. 9.4.2 Europe Rare Disease Therapeutic Revenue by Application (2027-2032)
  9. 9.5 Europe Rare Disease Therapeutic Revenue Share by Application (2021-2032)
  10. 9.6 Europe Rare Disease Therapeutic Revenue by Country
  11. 9.6.1 Europe Rare Disease Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Rare Disease Therapeutic Revenue by Country (2021-2026)
  13. 9.6.3 Europe Rare Disease Therapeutic Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Rare Disease Therapeutic Revenue (2021-2032)
  2. 10.2 China Rare Disease Therapeutic Revenue by Type (2021-2032)
  3. 10.2.1 China Rare Disease Therapeutic Revenue by Type (2021-2026)
  4. 10.2.2 China Rare Disease Therapeutic Revenue by Type (2027-2032)
  5. 10.3 China Rare Disease Therapeutic Revenue Share by Type (2021-2032)
  6. 10.4 China Rare Disease Therapeutic Revenue by Application (2021-2032)
  7. 10.4.1 China Rare Disease Therapeutic Revenue by Application (2021-2026)
  8. 10.4.2 China Rare Disease Therapeutic Revenue by Application (2027-2032)
  9. 10.5 China Rare Disease Therapeutic Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Rare Disease Therapeutic Revenue (2021-2032)
  2. 11.2 Asia Rare Disease Therapeutic Revenue by Type (2021-2032)
  3. 11.2.1 Asia Rare Disease Therapeutic Revenue by Type (2021-2026)
  4. 11.2.2 Asia Rare Disease Therapeutic Revenue by Type (2027-2032)
  5. 11.3 Asia Rare Disease Therapeutic Revenue Share by Type (2021-2032)
  6. 11.4 Asia Rare Disease Therapeutic Revenue by Application (2021-2032)
  7. 11.4.1 Asia Rare Disease Therapeutic Revenue by Application (2021-2026)
  8. 11.4.2 Asia Rare Disease Therapeutic Revenue by Application (2027-2032)
  9. 11.5 Asia Rare Disease Therapeutic Revenue Share by Application (2021-2032)
  10. 11.6 Asia Rare Disease Therapeutic Revenue by Country
  11. 11.6.1 Asia Rare Disease Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Rare Disease Therapeutic Revenue by Country (2021-2026)
  13. 11.6.3 Asia Rare Disease Therapeutic Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Rare Disease Therapeutic Revenue (2021-2032)
  2. 12.2 SAMEA Rare Disease Therapeutic Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Rare Disease Therapeutic Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Rare Disease Therapeutic Revenue by Type (2027-2032)
  5. 12.3 SAMEA Rare Disease Therapeutic Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Rare Disease Therapeutic Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Rare Disease Therapeutic Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Rare Disease Therapeutic Revenue by Application (2027-2032)
  9. 12.5 SAMEA Rare Disease Therapeutic Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Rare Disease Therapeutic Revenue by Country
  11. 12.6.1 SAMEA Rare Disease Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Rare Disease Therapeutic Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Rare Disease Therapeutic Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst